Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 5/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983210 | 1.00 | MMP2 (0.56) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL2032499 | 1.00 | MMP2 (0.56) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL29630808 | 0.99 | MMP2 (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30051999 | 0.95 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30051480 | 0.95 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL23142823 | 0.95 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL23142822 | 0.95 | CTSB (0.55) | MMP2ITGB3ITGA2BMMEACE | |
| SCHEMBL30997458 | 0.91 | QRFPR (0.54) | MMP2ITGB3ITGA2BMME | |
| SCHEMBL30439820 | 0.91 | OPRD1 (0.52) | ITGB3ITGA2BMMECTSCLMNA | |
| SCHEMBL30439797 | 0.91 | OPRD1 (0.52) | ITGB3ITGA2BMMECTSCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| CN-119855820-A | Camptothecins compound and its preparation method and use | 上海齐鲁制药研究中心有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| CN-118922447-A | Folate receptor alpha-targeting antibody-drug conjugates and methods of use | 酵活英属哥伦比亚有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201641-A | Novel degradant-anti-CD 33 antibody conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| US-20110144065-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | U.S. DEPARTMENT OF ENERGY | 2011-06-16 | — | — | US | disclosed |
| US-20100184702-A1 | Selective High-Affinity Polydentate Ligands and Methods of Making Such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2010-07-22 | — | — | US | disclosed |
| US-7662785-B2 | Selective high affinity polydentate ligands and methods of making such | THE REGENTS OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060084115-A1 | Selective high affinity polydentate ligands and methods of making such | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-04-20 | — | — | US | disclosed |
| US-5573748-A | KIT FOR USE IN PREPARING THE CHELATE; CONTAINER WITH GLYCYLGLYCYL LIGAND, WATER SOLUBLE STANNOUS SALT, INTERMEDIATE EXCHANGE LIGAND, WATER SOLUBLE TECHNETIUM-99M PERTECHNETATE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1996-11-12 | — | — | US | disclosed |
| US-5322929-A | Tri- and tetrapeptides as ligands | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1994-06-21 | — | — | US | disclosed |
| US-4980147-A | INJECTING AS IMAGING AGENTS IN SCINTIGRAPHIC UROGRAPHY | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0173424-A1 | Radiolabeled technetium chelates for use in renal function determinations | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1986-03-05 | — | — | EP | disclosed |
| US-4219337-A | COOMASSIE BRILLIANT BLUE G250 FOR COLORIMETRIC ANALYSIS | THE MEDICAL COLLEGE OF WISCONSIN (US) | 1980-08-26 | — | — | US | disclosed |
| US-4181649-A | GEL CHROMATOGRAPHY, CROSSLINKED STRACH GEL | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | MMP2 4843/4885ITGB3 2688/4885ITGA2B 1525/4885 |
| US-20110144065-A1 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH | CD44, FCGR3B, FCGR2A | MMP2 4144/4885ITGB3 1448/4885ITGA2B 1750/4885 |
| US-20100184702-A1 | Selective High-Affinity Polydentate Ligands and Methods of Making Such | CD44, FCGR3B, FCGR2A | MMP2 4144/4885ITGB3 1448/4885ITGA2B 1750/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | MMP2 4798/4885ITGB3 2490/4885ITGA2B 1374/4885 |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | MMP2 2356/4885ITGB3 3528/4885ITGA2B 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.